Clinical trials recruiting in Qingyuan, China

Phase breakdown

Conditions recruiting in Qingyuan, China

Recruiting trials in Qingyuan, China

• A Real World, Multi-centric, Observational Registry Study of Chronic Kidney Diseases
  NCT05188885 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07288554 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
  NCT05837897 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female)
• A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
  NCT07292714 · Phase: Phase 2 · Ages: 40 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
  NCT07635186 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• ASPIrin in Reducing Events in Dialysis ( ASPIRED )
  NCT04381143 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
  NCT07184931 · Phase: Phase 3 · Ages: 16 Years to 80 Years · Sex: All (male and female)
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
  NCT06569524 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Phase II Study of RC1416 Injection in COPD
  NCT07402551 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Qingyuan, China?

13 recruiting trials have at least one study site in Qingyuan, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.